2 Best Biotech Stocks to Buy in November

Motley Fool2021-11-02

Biotech stocks appear to be poised for a strong showing in November for a host of reasons. First and foremost, the industry's biggest headwind this year -- drug pricing reform -- was conspicuously ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Reminiscent
2021-11-02
Reminiscent
My retirement stock for the future 🚀
ethanolll
2021-11-02
ethanolll
ok
- ethanolll:
  👍
Moonlight10
2021-11-02
Moonlight10
Hello
Wallstrtbets
2021-11-02
Wallstrtbets
Not heard of.

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1135028228?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-02 11:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135028228","market":"us","top_or_hot":-1,"title":"2 Best Biotech Stocks to Buy in November","media":"Motley Fool","content":"<div>\n<p>Biotech stocks appear to be poised for a strong showing in November for a host of reasons. First and foremost, the industry's biggest headwind this year -- drug pricing reform -- was conspicuously ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/01/2-best-biotech-stocks-to-buy-in-november/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Best Biotech Stocks to Buy in November</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Best Biotech Stocks to Buy in November\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-02 11:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/01/2-best-biotech-stocks-to-buy-in-november/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech stocks appear to be poised for a strong showing in November for a host of reasons. First and foremost, the industry's biggest headwind this year -- drug pricing reform -- was conspicuously ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/01/2-best-biotech-stocks-to-buy-in-november/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNGO","symbol_name":"Bionano Genomics","start_time":0,"source_url":"https://www.fool.com/investing/2021/11/01/2-best-biotech-stocks-to-buy-in-november/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","article_id":"1135028228","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135028228","pubTimestamp":1635822901,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"Biotech stocks appear to be poised for a strong showing in November for a host of reasons. First and","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNGO":"Bionano Genomics","OCGN":"Ocugen"},"translate_title":"11月最值得买入的2只生物科技股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNGO":0.9,"OCGN":0.9},"content_text":"Biotech stocks appear to be poised for a strong showing in November for a host of reasons. First and foremost, the industry's biggest headwind this year -- drug pricing reform -- was conspicuously left out of the social spending bill recently released by the White House. Second, the latest earnings reports from top big pharma companies like Merck have been better than expectedso far. Lastly, scores of drugmakers are slated to release key clinical and regulatory updates this month.\nWhich biotech stocks could be the belles of the ball in November?Bionano Genomics(NASDAQ:BNGO)and Ocugen(NASDAQ:OCGN)are two names that growth-oriented investors should definitely have on the radars this month. Here's why.\nBionano Genomics: Time to buy this fallen angel\nPersonalized medicine is the holy grail of biotech research. Despite numerous breakthroughs in the treatment of cancer with the advent of immunotherapy, a clinical success in this field is generally characterized by response rates as low as 30%. Researchers believe that these exceedingly low response rates stem from differences in the mutation type at both the nucleic acid and whole chromosomal level within a particular patient population. Cancer, in effect, is not a monolithic disease, making it impossible to develop a one-size-fits-all type of therapy.\nTo boost the efficacy of these novel anti-cancer treatments, researchers thus require an accurate picture of the malignancy's genetic architecture at the individual level. That's where a company like Bionano Genomics comes into play. Bionano Genomicssportsa non-sequencing-based optical mapping technology known as the Saphyr System. The Saphyr System is designed to rapidly characterize extremely long strands of genomic DNA.\nWhat's more, the biotech recently acquired the leading genomics data analysis software company BioDiscovery. This landmark acquisition could turn out to be a game-changing business development move for the company and its shareholders. In brief, BioDiscovery's NXClinical software solution for variant analysis, combined with the Saphyr System, has the potential to accelerate the adoption of optical genome mapping at large. Moreover, this potentially best-in-class platform might ultimately grab an outsize portion of this multi-billion dollar market within the next few years.\nWhy should investors buy this stock in November? Bionano is slated to report third-quarter earnings on Nov. 4. While the biotech's Q3 revenue figure is unlikely to turn heads, investors should learn more about the long-term implications of this key acquisition. As a result, Bionano's beaten-down stock might finally start to show some signs of life after an eight-month downturn. Underscoring this point, the biotech's shares are currently down by a whopping 67% relative to their 52-week highs. Aggressive investors, in turn, may want to pick up some shares ahead of this upcoming earnings report.\nOcugen: An underappreciated COVID-19 vaccine stock\nThanks to its popularity onsocial media, Ocugen's shares have jumped by an astounding 547% so far this year. The biotech's appeal to the social media crowd isn't without reason, however. Ocugen's North American co-commercialization agreement with India's Bharat Biotech for the COVID-19 vaccine Covaxin is expected to lead to a monstrous rise in its top line in 2022 and beyond. Wall Street, in fact, thinks the vaccine's North American sales may top $400 million within the next two years.\nWhile this experimental vaccine still has to undergo clinical testing in the U.S., as well as a regulatory review in Canada, before Ocugen can start earning revenue from it, the vaccine does appear to workfairly wellbased on its clinical trial data in India. As such, there is a solid basis to believe that this vaccine will eventually be approved in the U.S. and Canada.\nWhy is Ocugen's stock a strong buy this month? Ocugen and its partner Bharat Biotech are expecting to receive word on the vaccine's emergency use listing (EUL) application from the World Health Organization (WHO) soon. The WHO has repeatedly asked Bharat Biotech for additional data prior to approving an EUL for Covaxin, leading to a lengthy delay for this key regulatory nod. But a green light could come as soon as Nov. 3, when the WHO's technical advisory group overseeing vaccine EULs meets again.\nAlthough Ocugen will not financially benefit from a WHO EUL due to the nature of its co-commercialization agreement with Bharat Biotech, it would be huge step in the right direction for the experimental vaccine. The biotech's stock, in turn, will likely continue to march higher in response to a positive EUL decision this month.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":841072224,"gmtCreate":1635865742259,"gmtModify":1635866541326,"author":{"id":"3567060979533928","authorId":"3567060979533928","name":"Reminiscent","avatar":"https://static.tigerbbs.com/756f10ded1f79212c0f44c111c0d9278","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3567060979533928","authorIdStr":"3567060979533928"},"htmlText":"My retirement stock for the future 🚀&nbsp;","listText":"My retirement stock for the future 🚀&nbsp;","text":"My retirement stock for the future 🚀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841072224","repostId":1135028228,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":843247842,"gmtCreate":1635837108725,"gmtModify":1635837108907,"author":{"id":"3580097723820791","authorId":"3580097723820791","name":"ethanolll","avatar":"https://static.tigerbbs.com/d0541395faed1506636b2f0dcd1699d5","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3580097723820791","authorIdStr":"3580097723820791"},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/843247842","repostId":1135028228,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6422560,"gmtCreate":1635837119672,"gmtModify":1635837119801,"authorId":3580097723820791,"author":{"id":3580097723820791,"idStr":"3580097723820791","authorId":3580097723820791,"name":"ethanolll","avatar":"https://static.tigerbbs.com/d0541395faed1506636b2f0dcd1699d5","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":843247842,"type":1,"supId":0,"prevId":0,"content":"👍","text":"👍","html":"👍"}],"langContent":"CN"},{"id":843208299,"gmtCreate":1635828666139,"gmtModify":1635828666139,"author":{"id":"3573357249671764","authorId":"3573357249671764","name":"Moonlight10","avatar":"https://static.tigerbbs.com/a0b198d5f315294dab103e319e5fbcf6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573357249671764","authorIdStr":"3573357249671764"},"htmlText":"Hello","listText":"Hello","text":"Hello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843208299","repostId":1135028228,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":843627040,"gmtCreate":1635825956722,"gmtModify":1635825957768,"author":{"id":"3566244878628904","authorId":"3566244878628904","name":"Wallstrtbets","avatar":"https://static.tigerbbs.com/6c38bbee1121ea92508ad9508fa15c5e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3566244878628904","authorIdStr":"3566244878628904"},"htmlText":"Not heard of.","listText":"Not heard of.","text":"Not heard of.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843627040","repostId":1135028228,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":40,"commentSize":4,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135028228"}